U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07094477) titled 'Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma' on June 01.
Brief Summary: The purpose of this study is to determine the efficacy and safety of targeted CD22/CD19 CAR-T cell immunotherapy for first-line consolidation therapy of high-risk invasive B-cell lymphoma.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Lymphoma
Intervention:
DRUG: CD22/CD19 CAR-T cell immunotherapy
targeted CD22/CD19 CAR-T cell immunotherapy
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: Daihong Liu
Information provided by (Responsible Party): Daihong Liu, Chinese PLA General Hospital...